Celgene to Acquire Quanticel Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Celgene (CELG) to Acquire Quanticel Pharma in $485M Deal
April 27, 2015 7:31 AM EDTCelgene (NASDAQ: CELG) and Quanticel Pharmaceuticals, Inc., a privately held biotechnology company focused on cancer drug discovery, today announced a definitive share purchase agreement under which Celgene Corporation will acquire Quanticel. Through the agreement, Celgene will have full access to Quanticels proprietary platform for the single-cell genomic analysis of human cancer, as well as Quanticels lead programs that target specific epigenetic modifiers to advance Celgenes pipeline of innovative cancer therapies.
The acquisition culminates a 2011 strategic alliance between Celgene and Quanticel. Over the course of the three-and-a-half year alliance,... More
